Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2011 by Sun Farm Corporation
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Sun Farm Corporation
ClinicalTrials.gov Identifier:
NCT00246727
First received: October 27, 2005
Last updated: October 28, 2011
Last verified: October 2011
  Purpose

The primary objective of these two studies is to test the hypothesis that the daily ingestion of a dietary supplement, Selected Vegetables and Herbs Mix (SV), which consists of non-toxic botanicals containing known anti-cancer and/or immune enhancing components, may prolong the survival time of stage IIIB/IV non-small cell lung cancer (NSCLC) patients. Either SV or placebo will be added to their daily diet in a double-blind randomized fashion, so that there will be 2 chances out of 3 of receiving SV and 1 chance out of 3 of receiving placebo.

  • Study 1: For newly diagnosed patients who will be receiving or have received less than 4 weeks of, a standard chemotherapy regimen.
  • Study 2: For those who have stopped or refuse standard chemotherapy but will receive best supportive care.

Condition Intervention Phase
Non-small Cell Lung Cancer
Drug: Selected Vegetable and Herb Mix
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Study 1: Effects of a Dietary Supplement (SV) on Advanced NSCLC Treated With Chemotherapy: A Randomized Double Blind Placebo Controlled Study; Study 2: Effects of a Dietary Supplement (SV) on Advanced NSCLC Treated With Best Supportive Care: A Randomized Double Blind Placebo Controlled Study

Resource links provided by NLM:


Further study details as provided by Sun Farm Corporation:

Primary Outcome Measures:
  • Survival Time [ Time Frame: Median Survival Time (MST) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tumor response [ Time Frame: After one month of treatment ] [ Designated as safety issue: No ]
  • Quality of Life [ Time Frame: For length of study while on active treatment ] [ Designated as safety issue: No ]
  • Toxicity of SV [ Time Frame: Annually ] [ Designated as safety issue: Yes ]
    Assessed anually at Safety Monitoring Board


Estimated Enrollment: 300
Study Start Date: December 2005
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Study 1: Chemotherapy plus SV or Placebo
For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.
Drug: Selected Vegetable and Herb Mix
The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
Placebo Comparator: Study 2: SV vs Placebo without chemotherapy
For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
Drug: Selected Vegetable and Herb Mix
The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.

Detailed Description:

Carcinoma of the lung is the leading cause of cancer related deaths in North America. Non-small Cell Lung Cancer (NSCLC) causes the death of more than 400,000 patients annually in the US and Western Europe. The benefit of conventional therapies, such as chemotherapy and radiotherapy, for unresectable stage IIIB and IV NSCLC patients is small; the generally accepted median survival time of late stage patients has remained 4-6 months in the "Supportive Care" group and 6-9 months in the chemotherapy treatment group; the one-year survival is about 20%. Ideal Treatment for NSCLC: The toxicity of chemotherapy and side-effects of radiotherapy to the quality of life of the patients have been a major issue in cancer treatments. It has been significant enough that many patients choose to forgo standard treatments. Furthermore, the current chemotherapy for advanced NSCLC is quite expensive, about $50,000 to $100,000 per year. Therefore, an ideal treatment for advanced NSCLC patients should meet the following criteria:

  1. Prolong patient survival.
  2. Minimal toxicity.
  3. Improvement in the patient's quality of life.
  4. Relatively inexpensive. A phytomix consisting of selected vegetables and herbs appears to meet all these criteria. The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.

The Objectives of the proposed studies are to evaluate the benefits and adverse reactions of adding SV to the daily diet of cancer patients who are willing to undergo the chemotherapy (Study 1) or those who refuse chemotherapy (Study 2).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathological and radiographic documented stage IIIB/IV NSCLC (squamous, adenocarcinoma, bronchioloalveolar, large cell, undifferentiated or not otherwise specified non-small cell carcinoma) diagnosed less than two months prior to randomization. Patients must have ECOG performance status of 0-1 and life expectancy >3 months.
  • Patients must never have been diagnosed with any malignancy other than the current NSCLC, except for non-metastatic non-melanoma skin cancer, or cancer in situ of the cervix.
  • Patients must be >18 years of age.
  • Patients must demonstrate the ability and willingness to eat solid food and SV/placebo.
  • Patients must demonstrate the ability and willingness to give informed consent.
  • Patients must demonstrate the ability and willingness to follow the study requirements.

Exclusion Criteria:

  • Laboratory criteria for exclusion within 14 days prior to randomization.

    • Liver function: bilirubin > 1.5x upper limit of normal (ULN) and SGOT (AST) > 2.5x ULN.
    • Renal function: Serum creatinine >1.5x ULN
    • Bone marrow function: white blood cell (WBC) < 4,000/µl; platelet count < 100,000 mm3; neutrophil count < 1,500/mm3.
    • Hemoglobin <9 gm/dl for males; < 8.5 gm/dl for females.
  • Unexplained temperature > 38.5° C for any 7 consecutive days or chronic diarrhea defined as > 3 stools/day persisting for 15 consecutive days, within the 30 days prior to randomization.
  • Prior chemotherapy within 5 years.
  • Prior radiation to the area of measurable or active tumor.
  • Significant cardiac disease (i.e. uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous year) or serious cardiac arrhythmia requiring medication.
  • Evidence of clinically significant neuropathy (> Grade 1) by physical exam.
  • Patients must not be pregnant or breast-feeding. Female patients of child-bearing potential must have a negative pregnancy test performed within 72 hours prior to randomization. Women of child-bearing potential must agree not to become pregnant while participating in the study.
  • Active acute infection, except for Herpes viruses (cytomegalovirus [CMV], Epstein Barr virus [EBV], herpes zoster virus [HZV], herpes simplex virus 1 [HSV 1]).
  • A serious underlying medical condition other than NSCLC such that life expectancy is less than 2 years.
  • Psychiatric illness that may affect the patient's compliance with the treatment.
  • Current use of illicit drugs, glucocorticoids other than those necessary for concurrent radiotherapy, adrenal failure or septic shock, or other immune-suppressing or immune-modulating drugs. Glucocorticoids for anti-emetic prophylaxis and therapy should only be used as a last resort.
  • A known allergy to one or more components of SV, namely soy beans, mushrooms, mung beans, red dates, scallion, garlic, lentil beans, leek, hawthorn fruit, onions, ginseng, angelica root, Chinese licorice, dandelion root, Senegal root, ginger, olives, sesame seed and parsley.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00246727

Contacts
Contact: Henry Sacks, MD, Ph.D 212-241-7856 henry.sacks@mssm.edu

Locations
United States, New York
Mount Sinai School of Medicine Recruiting
New York, New York, United States, 10029
Contact: Henry S Sacks, MD, Ph.D    212-241-7856    henry.sacks@mssm.edu   
Principal Investigator: Henry S Sacks, MD, Ph.D         
Sponsors and Collaborators
Sun Farm Corporation
Investigators
Principal Investigator: Henry S Sacks, MD, Ph.D Mount Sinai School of Medicine
  More Information

No publications provided

Responsible Party: Sun Farm Corporation
ClinicalTrials.gov Identifier: NCT00246727     History of Changes
Obsolete Identifiers: NCT00352274, NCT00392626
Other Study ID Numbers: SV-001 and SV-002
Study First Received: October 27, 2005
Last Updated: October 28, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 21, 2014